TickerTalks
Browse all tickers →
TickerTalks›$GSK
GSGSK

GSK plc

$GSK·$106B·Drug Manufacturers - General·Healthcare
$53.34+0.9%YTD+7.4%1Y+27.0%
Mentions · last 7 days
2026-06-05: 26 posts2026-06-06: 30 posts2026-06-07: 52 posts2026-06-08: 77 posts2026-06-09: 183 posts2026-06-10: 75 posts2026-06-11: 34 posts477+8%
Price updated 11m ago·X counts updated 21h ago
GSGSK
GSK plc$GSK
$53.34+0.90%477 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $GSK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-06-12

The move is getting stronger, with heavier trading behind it.

GSK announced $10.6B Nuvalent acquisition for oncology rebuild — Project Nashville positioning GSK as a serious oncology M&A buyer.

GSK is the UK-based pharma giant — HIV (Tivicay/Dovato), oncology, vaccines, respiratory. The company just announced an $11B+ acquisition of Nuvalent to anchor its oncology rebuild under the Project Nashville strategy. Q1 revenue grew 1.5% YoY to $7.63B at 22.3% operating margin and EPS of $0.86 — modest organic growth with strong margins. At 13.5x trailing earnings and 2.4x sales the multiple is below the pharma-peer average, reflecting concerns about patent-cliff exposure ahead. The June 11 Nuvalent acquisition at $10.6B is the strategic catalyst — Project Nashville positions GSK as a buyer for the next oncology leg, complementing the Jemperli (anti-PD-1) and BLENREP (BCMA) franchises. The gurufocus 'Is GSK Overvalued After 3.3% Rally' framing reflects the post-deal-announcement pop. Zero insider activity in the window. The Pharma and Biotech M&A Boom Accelerating framing places GSK among active strategic buyers.

What to watch: Nuvalent deal close timeline (typical 6-9 months subject to FTC/HSR/UK CMA review), Q2 print July 28 for organic-growth direction and any commentary on the Nuvalent acquisition integration plans. Continued GSK M&A activity given Project Nashville's open competitive process is the structural variable.

On the calendar: 2026-07-28 — Q2 earnings

no sentiment

Read the AI verdict + X sentiment for $GSK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $GSK.

Drug Manufacturers - General · Healthcare

The GLP-1 oral formulation race is the structural catalyst — NVO's oral semaglutide competes with LLY's injectable Zepbound for the obesity market's compliance-driven adoption curve. Large-cap pharma (ABBV, MRK, AZN) is deploying GLP-1 pipeline investments while managing LOE cliffs on legacy franchises.

See how Drug Manufacturers - General shapes $GSK

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $GSK's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+11.8%YTD
+41.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
13.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
22.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
35.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$1.24$1.16+6.9%
Q4 2025Feb 4, 2026$0.68$0.64+6.3%
Q3 2025Oct 29, 2025$1.48$1.26+17.5%
Q2 2025Jul 30, 2025$0.96——
Next earningsTue, Jul 28·consensus EPS $1.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.6B+1.5%75.4%30.1%$0.86$698.0M
Q4 FY25$8.6B+6.2%69.2%17.5%$0.84$1.5B
Q3 FY25$8.5B+6.7%73.6%30.3%$1.00$2.6B
Q2 FY25$8.0B+1.3%72.9%25.3%$0.72$1.5B

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$45.4B$45.1B – $45.7B$4.79$4.73 – $4.9112
FY27$47.8B$44.7B – $49.3B$5.25$5.02 – $5.5814
FY28$49.2B$47.7B – $50.6B$5.51$5.07 – $6.4317
FY29$51.0B$49.3B – $52.4B$5.81$5.57 – $6.0214
FY30$50.3B$48.7B – $51.7B$5.93$5.68 – $6.148

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+6.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.9B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.295-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $GSK is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com·1d agoPharma and Biotech M&A Boom Accelerates as Companies Expand Pipelineszacks.com·1d agoPatent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·1d agoProject Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·2d agoGSK plc (GSK) M&A Call Transcriptseekingalpha.com·2d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$ABBV$JNJ$PFE$GILD$BMY$MRK$AMGN
Voices on X · last 7 days

No standout posts about $GSK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport